Melanoma is considered to be the most life-threatening form of skin cancer. However, in recent decades the emergence of immunotherapy has made great strides in improving survival. What are the mortality rates for patients with melanoma and how have they changed?
Pembrolizumab significantly improved distant metastasis-free survival and reduced recurrence in stage IIB and IIC melanoma.
Investigators observed a complete response in more than half of patients treated with tislelizumab plus nab-paclitaxel for high-risk NMIBC that was not completely resectable.
In a phase 1 trial, investigators tested whether an oral supplement containing a strain of Clostridium butyricum increases the abundance of certain gut bacteria known to be associated with a better response to immune checkpoint inhibitors.
Progression on bacillus Calmette-Guérin (BCG) likely represents a biologically aggressive disease state as well as diagnostic delay, according to investigators.
Real-world data validate recently reported findings from clinical trials.
Immune checkpoint inhibitors prolonged survival when compared with chemotherapy.
Response endpoints were not strongly correlated with overall survival at the trial level.
There was no improvement in progression-free or overall survival.
Multiple myeloma (MM) is not a disease with a known cure, but recent studies have suggested that focusing on boosting immunity in patients with MM may help their chances at longer-term survival. What are these immunity-focused treatment options?
